|Dr. Richard M. Toselli||Pres, CEO, Chief Medical Officer & Director||N/A||N/A||1958|
|Mr. Mark D. Perrin||Consultant||741.94k||N/A||1957|
|Dr. Robert S. Langer Jr.||Co-Founder and Member of Scientific Advisory Board||N/A||N/A||1949|
|Dr. Joseph Philip Vacanti||Co-Founder||N/A||N/A||1949|
|Mr. Jeffrey Modestino||Principal Financial Officer, Principal Accounting Officer & Treasurer||N/A||N/A||N/A|
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for implantation at the site of injury within a spinal cord. The company was founded in 2005 and is headquartered in Cambridge, Massachusetts.
InVivo Therapeutics Holdings Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.